Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection

NCT05677113 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT05677113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2023
Completion date
February 1, 2031
Enrollment
115 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, liver metastases